Dave Levitan

A case series of rare peripheral T-cell lymphoma that is associated with breast implants found that most cases have an indolent clinical course.

The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers.

The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial, ovarian, and triple-negative breast cancers.

Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab vs ipilimumab in patients with stage III and IV resected melanoma.

The addition of abemaciclib to fulvestrant significantly improved PFS and time to subsequent chemotherapy in pre- and perimenopausal HR-positive/HER2-negative breast cancer patients.

The combination of ribociclib and fulvestrant yielded an improvement in progression-free survival in postmenopausal women with advanced breast cancer, according to the MONALEESA-3 trial.

Several different driver mutations acquired during treatment for breast cancer can help explain acquired resistance to the combination of palbociclib and fulvestrant.

Ribociclib plus endocrine therapy resulted in improved PFS in premenopausal women with HR+, HER2− advanced breast cancer.

Deeper inhibition of the MAPK pathway by targeting both MEK and BRAF may help improve progression-free survival outcomes in patients with advanced BRAF V600–mutated melanoma.

A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone.

The presence and burden of single nucleotide variants as measured in cell-free DNA may have substantial prognostic utility in patients with melanoma who have metastases.

Researchers have developed a “disease screening pill” that could allow for a noninvasive and safe method for detecting breast cancer using only near-infrared light.

Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.

New research has found that expression of AXL is correlated with poor outcomes in patients with HER2-positive breast cancer.

An intravesical instillation of gemcitabine following TURBT reduced the risk of recurrence in patients with suspected low-grade non–muscle-invasive urothelial cancer.

A neoadjuvant dose-dense regimen was active and well tolerated in patients with muscle-invasive bladder cancer, allowing downstaging of most patients before radical cystectomy.

The US Preventive Services Task Force issued a final recommendation on prostate cancer screening, including that men aged 55 to 69 years should make an individual decision on whether or not to be screened.

An analysis of patient-reported outcomes showed that osimertinib yielded a longer time to deterioration compared with chemotherapy in patients with advanced non–small-cell lung cancer.

The FDA granted approval to the combination of dabrafenib and trametinib for the adjuvant treatment of melanoma, specifically in patients with a BRAF V600E or V600K mutation.

A laboratory study has found that the HER2 inhibitor lapatinib used to slow HER2-positive breast cancer can actually induce tumor growth in some circumstances.

An at-home online survey was found to be a reasonably accurate way to collect patient comorbidities prior to a physician visit in patients with prostate cancer.

Researchers have developed a new model to help predict the development of breast cancer in women with atypical hyperplasia based on a breast biopsy.

Alectinib offered significantly improved outcomes over standard chemotherapy in patients with ALK-positive non–small-cell lung cancer who had progressed on crizotinib therapy.

Melanoma patients who are married tend to present at earlier stages of the disease than those who are not married, divorced, or widowed; marital status was also associated with the likelihood of undergoing SLNB.

A study found some mutations that are already targeted by approved or investigational drugs for prostate cancer, along with dozens of targets that should be considered as candidates for future trials.

Neoadjuvant nivolumab combo proved safe while yielding high response rates in patients with NSCLC.

In KEYNOTE-189, a pembrolizumab/chemo combination yielded OS and PFS benefits in patients with advanced NSCLC.

A simple prognostic tool could be used to identify patients with HR-positive breast cancer who underwent 5 years of endocrine treatment and who might be at higher risk of late distant recurrence.

Treatment with the TLR9 agonist CMP-001 appeared to potentially reverse resistance to immune checkpoint inhibition in patients with metastatic melanoma.

A personalized cancer vaccine was well tolerated and was capable of inducing antitumor T-cell immunity in patients with recurrent ovarian cancer.